Ott_a_214829 1717..1721

Huiwen Ma Jun Fang Ting Wang Donglin Wang Lulu Wang Chunmei Wang Long Tang Ying Tang Songmei Lu Yimin Wang Xingyue Chen 1Department of Oncology, Chongqing University Cancer Hospital, Chongqing University, Chongqing 400025, People’s Republic of China; 2First Department of Cardiothoracic Surgery, Chongqing Kanghuazhonglian Cardiovascular Disease Hospital, Chongqing 400025, People’s Republic of China Objective: To evaluate the efficacy and safety of apatinib in patients with relapse after surgery for fibrosarcoma. Methods: We reviewed the clinical data of 56 patients who experienced recurrence after fibrosarcoma resection and who received chemotherapy from September 2015 to September 2017 (no significant difference in general data of patients) (p>0.05). Differences in drug use and adverse effects were observed between patients who received monotherapy and those who received regular chemotherapy (MAID/AI). Results: Compared with the regular chemotherapy group, patients in the apatinib monotherapy group exhibited an improved overall response rate (ORR) and disease control rate (DCR). In patients treated with apatinib, the incidence of adverse reactions was improved, and the symptoms were mild (P<0.05). Conclusion: Apatinib is a single-drug regimen that can be used in cases of recurrence of fibrosarcoma with high expression of vascular endothelial growth factor receptor-2 (VEGFR2); its short-term efficacy is excellent, and its side effects are minimal. This drug may be used as part of a regular chemotherapy program.